Immune Checkpoint Inhibitors Rechallenge Efficacy in Non–Small-Cell Lung Cancer Patients

Elisa Gobbini, Anne Claire Toffart, Maurice Pérol, Jean Baptiste Assié, Michaël Duruisseaux, Dahna Coupez, Catherine Dubos, Virginie Westeel, Myriam Delaunay, Florian Guisier, Rémi Veillon, Valérie Gounant, Etienne Giroux Leprieur, François Roger Vanel, Nouha Chaabane, Eric Dansin, Hélène Babey, Chantal Decroisette, Fabrice Barlesi, Catherine DanielPierre Fournel, Laura Mezquita, Youssef Oulkhouir, Anthony Canellas, Boris Duchemann, Olivier Molinier, Vincent Alcazer, Denis Moro-Sibilot, Matteo Giaj Levra

Research output: Contribution to journalArticlepeer-review

51 Citations (Scopus)

Abstract

Immune checkpoint inhibitor (ICPi) rechallenge could represent an attractive option in non–small-cell lung cancer (NSCLC), yet no sufficient data support this strategy. Our retrospective study explored the efficacy of ICPi rechallenge in 144 advanced NSCLC patients. It might be an option in patients discontinuing the first ICPi for toxicity or clinical reasons, those able to maintain a treatment-free period, and those with a good Eastern Cooperative Oncology Group performance status score.

Original languageEnglish
Pages (from-to)e497-e510
JournalClinical Lung Cancer
Volume21
Issue number5
DOIs
Publication statusPublished - 1 Sept 2020
Externally publishedYes

Keywords

  • Efficacy
  • Immune checkpoint inhibitors
  • NSCLC
  • Re-challenge
  • Selection criteria

Cite this